Where does PRME stock trade?

Prime Medicine Inc. (PRME) is listed on NASDAQ.

What sector and industry is PRME in?

Prime Medicine Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.

When did Prime Medicine Inc. go public?

Prime Medicine Inc. (PRME) completed its IPO in 2022.

What are analysts saying about PRME?

Prime Medicine Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $1100.00 price target on 2026-03-12.

What companies are similar to PRME?

Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare PRME side-by-side with any of them on Quantisnow.

How can I track PRME on Quantisnow?

Quantisnow aggregates Prime Medicine Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRME to receive live email and push alerts on every new disclosure.

PRME

NASDAQ

Prime Medicine Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2022

$2.82+0.11 (+4.06%)

News25/Ratings12

Price$2.82+0.11 (+4.06%)

01:30 PM07:45 PM

News · 26 weeks33+100%

2025-12-142026-06-07

Mix1990d

Insider9(47%)
SEC Filings6(32%)
Leadership2(11%)
Other2(11%)

Latest news

25 items

3dINSIDER
SEC Form 4 filed by Director Schenkein David P
4 - Prime Medicine, Inc. (0001894562) (Issuer)
3dINSIDER
SEC Form 4 filed by Director Marrazzo Jeffrey D
4 - Prime Medicine, Inc. (0001894562) (Issuer)
3dINSIDER
SEC Form 4 filed by Director Nelsen Robert
4 - Prime Medicine, Inc. (0001894562) (Issuer)
3dINSIDER
SEC Form 4 filed by Director Kelly Michael Aaron
4 - Prime Medicine, Inc. (0001894562) (Issuer)
3dINSIDER
SEC Form 4 filed by Director Foster-Cheek Kaye I
4 - Prime Medicine, Inc. (0001894562) (Issuer)
3dINSIDER
SEC Form 4 filed by Director Chung Wendy
4 - Prime Medicine, Inc. (0001894562) (Issuer)
3dINSIDER
SEC Form 4 filed by Director Cahill Thomas
4 - Prime Medicine, Inc. (0001894562) (Issuer)
3dSEC
Prime Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - Prime Medicine, Inc. (0001894562) (Filer)
8dPR
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET in Miami Beach, FL. A live audio webcast of the presentation will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 9
14dPR
Prime Medicine to Present at Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 12:50 p.m. ET in New York, NY. A live audio webcast of the presentation will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the e
35dSEC
SEC Form 10-Q filed by Prime Medicine Inc.
10-Q - Prime Medicine, Inc. (0001894562) (Filer)
35dSEC
Prime Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Prime Medicine, Inc. (0001894562) (Filer)
35dPR
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue with the FDA toward BLA filing for PM359 in CGD -- -- Strengthened leadership team with appointment of Svetlana Makhni as Chief Financial Officer -- -- Cash, cash equivalents, investments, and restricted cash of $149.2 million as of March 31, 2026, providing cash runway into 2027 -- CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today repor
49dSEC
SEC Form DEFA14A filed by Prime Medicine Inc.
DEFA14A - Prime Medicine, Inc. (0001894562) (Filer)
49dSEC
SEC Form DEF 14A filed by Prime Medicine Inc.
DEF 14A - Prime Medicine, Inc. (0001894562) (Filer)
54dINSIDER
SEC Form 4 filed by Makhni Svetlana Ni
4 - Prime Medicine, Inc. (0001894562) (Issuer)
54dINSIDER
SEC Form 3 filed by new insider Makhni Svetlana Ni
3 - Prime Medicine, Inc. (0001894562) (Issuer)
56dSEC
Prime Medicine Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - Prime Medicine, Inc. (0001894562) (Filer)
56dPR
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni will oversee Prime Medicine's financial operations and strategy, including investor relations, financial planning and analysis, and corporate development. "We are delighted to welcome Svetlana to Prime Medicine," said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. "Svetlana brings proven leadership at clinical-stage biotechnology companies, as well as deep capital markets experti
91dANALYST
Oppenheimer initiated coverage on Prime Medicine with a new price target
Oppenheimer initiated coverage of Prime Medicine with a rating of Outperform and set a new price target of $11.00
98dSEC
SEC Form EFFECT filed by Prime Medicine Inc.
EFFECT - Prime Medicine, Inc. (0001894562) (Filer)
100dSEC
SEC Form S-8 filed by Prime Medicine Inc.
S-8 - Prime Medicine, Inc. (0001894562) (Filer)
100dSEC
SEC Form POS AM filed by Prime Medicine Inc.
POS AM - Prime Medicine, Inc. (0001894562) (Filer)
100dSEC
SEC Form 10-K filed by Prime Medicine Inc.
10-K - Prime Medicine, Inc. (0001894562) (Filer)
100dSEC
SEC Form POSASR filed by Prime Medicine Inc.
POSASR - Prime Medicine, Inc. (0001894562) (Filer)

Analyst ratings

Last 12

Mar 12Oppenheimer•Update
Outperform$11.00▲ 290%
May 27Citigroup•Update
Neutral$1.50▼ 46.8%
May 20Analyst•Update
Neutral--
May 20H.C. Wainwright•Update
Neutral--
Dec 10JMP Securities•Update
Mkt Outperform$10.00▲ 255%
May 20H.C. Wainwright•Update
Buy$10.00▲ 255%
May 16Citigroup•Update
Buy$10.00▲ 255%
Apr 22Chardan Capital Markets•Update
Buy$17.00▲ 503%
Apr 8TD Cowen•Update
Buy--
Apr 3Wedbush•Update
Outperform$12.00▲ 326%
Jan 16Stifel•Update
Hold$9.00$18.00▲ 219%
Dec 8Citigroup•Update
Neutral$10.00▲ 255%

Short volume

34d, FINRA Reg SHO

60.6%Jun 11

34d avg 60.2%+0.4pp

Apr 24Short / total volumeJun 11

Short691.3KTotal1.14M

Options

5 expirations

Jun 18, 20266d

IV 125.9%5 exp · 80

Callsstrike · last · iv · Δ

1.002.50--
2.001.01--
3.000.10--
4.000.05--

Putsstrike · last · iv · Δ

1.00---
2.00---
3.000.32126%-0.56
4.001.38--

Peers

Quick links

PRME FAQ

6 questions

Where does PRME stock trade?
Prime Medicine Inc. (PRME) is listed on NASDAQ.
What sector and industry is PRME in?
Prime Medicine Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
When did Prime Medicine Inc. go public?
Prime Medicine Inc. (PRME) completed its IPO in 2022.
What are analysts saying about PRME?
Prime Medicine Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $1100.00 price target on 2026-03-12.
What companies are similar to PRME?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare PRME side-by-side with any of them on Quantisnow.
How can I track PRME on Quantisnow?
Quantisnow aggregates Prime Medicine Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRME to receive live email and push alerts on every new disclosure.